Trial reportSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Efficacy of Transfer Energy Capacitive and Resistive Therapy Combined With β-Hydroxy-β-Methylbutyrate Nutritional Supplementation in Older Adults With Sarcopenic Obesity].
Trial report in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the comprehensive intervention effects of transfer energy capacitive and resistive (TECAR) therapy combined with β-hydroxy-β-methylbutyrate (HMB) nutritional supplementation in older patients with sarcopenic obesity (SO). Methods: We conducted a randomized controlled trial, enrolling 140 older patients who met the Asian diagnostic criteria for SO. Participants were randomly assigned to 4 groups, including a double-placebo group (Group A), TECAR + placebo group (Group B), sham TECAR + HMB group (Group C), and TECAR + HMB group (Group D), with 35 patients in each group. The intervention lasted 12 weeks. The primary outcome measure was the total score of the Short Physical Performance Battery (SPPB). Secondary outcome indicators included the modified Barthel Index (MBI), scores of the Mini Nutritional Assessment-Short Form (MNA-SF), handgrip strength, body mass, and body mass index (BMI). A two-way analysis of variance (ANOVA) was used to assess the interaction effects between TECAR and HMB. Results: After the intervention, Group D (TECAR + HMB) demonstrated significant improvements across all metrics. The SPPB total score increased from 6.29 ± 1.34 to 8.06 ± 1.51 ( Conclusion: TECAR therapy combined with HMB supplementation significantly enhances physical function, activities of daily living, and body composition in elderly patients with sarcopenic obesity, demonstrating a synergistic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.